Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study by unknown
ORIGINAL RESEARCH
Impact of Medication Adherence and Persistence
on Clinical and Economic Outcomes in Patients
with Type 2 Diabetes Treated with Liraglutide:
A Retrospective Cohort Study
Erin K. Buysman • Fang Liu • Mette Hammer • Jakob Langer
To view enhanced content go to www.advancesintherapy.com
Received: February 17, 2015 / Published online: April 2, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Adherence to diabetes
medication has been linked to improved
glycemic levels and lower costs, but previous
research on adherence has typically involved
oral antidiabetic medication or insulin. This
study examines how adherence and persistence
to once-daily liraglutide impact glycemic
control and economic outcomes in a real-
world population of adult type 2 diabetes
(T2D) patients.
Methods: A retrospective cohort study using
administrative claims data from July 2009
through September 2013. Patients aged
C18 years with T2D treated with liraglutide
were identified (index date = first liraglutide
prescription). Adherence was based on the
proportion of days covered (PDC); with PDC
C0.80 classified as adherent. Non-persistent
patients were those with a gap in therapy of
[90 days. Lab results for glycated hemoglobin
(A1C) were used to identify whether patients
achieved target levels of\7.0% and B 6.5%, or
experienced a reduction of C1.0% in A1C from
pre-index (baseline) to post-index (follow-up).
Logistic regression was used to estimate the
likelihood of achieving the A1C goals, adjusted
for baseline characteristics. Diabetes-related
medical, pharmacy, and total costs were
modeled and estimated for the adherence and
persistence cohorts.
Results: A total of 1321 patients were
identified. The mean PDC was 0.59 and 34%
of patients were classified as adherent, while
60% were persistent over 12 months of follow-
up. Adherent and persistent patients were more
likely to achieve each of the A1C goals than
their non-adherent and non-persistent
counterparts after adjusting for patient
characteristics. Adherence and persistence were
associated with higher adjusted diabetes-related
pharmacy and total healthcare costs during
follow-up; whereas persistent patients had
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significantly lower diabetes-related medical
costs than non-persistent patients.
Conclusions: Adherence and persistence to
liraglutide are associated with improved A1C
outcomes. Persistent patients showed
significantly lower medical costs versus those
discontinuing liraglutide. Total healthcare costs
were higher for adherent and persistent cohorts
driven by higher pharmacy costs.
Keywords: Adherence; Diabetes; Glycemic
control; Economic outcomes; Hemoglobin
A1C; Liraglutide; Persistence
INTRODUCTION
In 2012, 29.1 million people in the US had
diabetes (roughly 9% of the US population),
including over 8 million who were undiagnosed
[1]. Type 2 diabetes (T2D) represents the large
majority of diabetes cases (90–95%) [1]. The
economic burden of diabetes is substantial, with
roughly $245 billion in total direct and indirect
costs in the US in 2012, including $176 billion in
direct medical costs [1, 2]. Diabetes is the leading
cause of blindness, end-stage renal disease, and
non-traumatic lower-extremity amputations, and
is a major risk factor for coronary artery disease
and stroke [3]. In 2010, diabetes was the seventh
leading cause of death in the US [1].
Treating diabetes may involve adjustments
to diet and lifestyle, as well as
pharmacotherapy. The main goal of treatment
is to maintain blood glucose to reduce the risk
of known complications [4]. The American
Diabetes Association recommends that the
target level for glycated hemoglobin (A1C) is
less than 7% [5], although only 57% achieved
that goal in 2003–2006 [6]. The American
Association of Clinical Endocrinologists
recommends a target for A1C of B6.5% [7].
Metformin (a biguanide) is recommended as
first-line treatment [8], with a variety of
therapies available as second- and third-line
agents if treatment with metformin is
insufficient to achieve desired A1C levels or if
patients exhibit intolerance to metformin.
Common classes of these second- and third-
line antidiabetic agents include sulfonylureas,
meglitinides, thiazolidinediones, glucagon-like
peptide-1 (GLP-1) receptor agonists, dipeptidyl
peptidase-4 (DPP-4) inhibitors, sodium–glucose
co-transporter 2 inhibitors and insulins.
Liraglutide is a long-acting, GLP-1 receptor
agonist administered through a once-daily
injection.
Adherence to diabetes medications is
generally poor [9, 10]. Several studies have
demonstrated a link between adherence and
diabetes-related outcomes, including A1C
levels [4, 10–15]. In one study, the lower
A1C achieved from greater adherence was
comparable to that achieved with additional
medication [16]. Persistence to prescription
fills has also shown to be associated with a
reduction in costs and rates of
hospitalizations within Medicare patients
[17]. However, previous research on
adherence and persistence to diabetes
medication is primarily limited to oral
antidiabetic (OAD) medications or insulin.
In short, there is a paucity of data examining
the association of adherence or persistence
and subsequent clinical outcomes and costs
within the GLP-1 receptor agonist therapeutic
space. To expand the current knowledge and
understanding of the clinical and economic
outcomes associated with liraglutide, we
sought to examine the impact of both
adherence and persistence to once-daily
liraglutide on glycemic control and
healthcare costs in a real-world adult T2D
population.
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METHODS
Study Design and Data Sources
A retrospective cohort study was conducted
using administrative claims from a large, US
health plan affiliated with Optum during July
2009 through September 2013. The
administrative claims database includes
demographic information as well as medical
data from physician and facilities or hospitals
and pharmacy data in the form of prescription
medication claims. There were approximately
18.5 million commercially insured adult
enrollees covered during the study period.
Individuals included in the database are
geographically diverse across the US, with the
greatest representation in the South and
Midwest regions. Claims include International
Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnosis
and procedure codes, Current Procedural
Terminology procedure codes, Healthcare
Common Procedure Coding System codes, site
of service codes, and health plan and patient
costs. Outpatient pharmacy data includes
National Drug Codes for dispensed
medications, quantity dispensed, drug
strength, days’ supply, and costs. Outpatient
lab results (including A1C) are available in
linked laboratory data for a subset of the
population.
Patient Selection
Adult commercial health plan members with
T2D who were treated with liraglutide were
included in the study. Specifically, those with at
least one pharmacy claim for liraglutide
between January 01, 2010 and September 30,
2012 were identified, and the index date was
defined as the date of the first liraglutide claim.
An indication of T2D was based on ICD-9-CM
diagnosis codes or claims for OADs during the
180 days prior to the index date (see ‘‘Appendix
1’’ for the algorithm). Additionally, subjects
were required to be at least 18 years old as of the
index year and have continuous enrollment in
the health plan with medical and pharmacy
benefits for 180 days prior to the index date
(baseline period) and for 365 days following the
index date (follow-up period). Subjects with
claims for GLP-1 agents during the baseline
period or evidence of pregnancy or gestational
diabetes during either the baseline or follow-up
periods were excluded. Finally, subjects were
required to have at least one A1C lab result
during the period 45 days prior to the index
date through 7 days after the index date and at
least one A1C lab result between 275 and
455 days after the index date (365 days post-
index ±90 days).
Study Measures
Adherence to liraglutide was based on the
proportion of days covered (PDC), which has
gained favor as the preferred adherence
measure. The PDC is used by the Pharmacy
Quality Alliance (PQA) in its most recent quality
measures [18], and the Centers for Medicare and
Medicaid Services (CMS) use PDC as a quality
measure of Part D plans in their Quality
Evaluation System [19]—a measure endorsed
by the National Quality Forum. The PDC is
calculated as the number of days the
medication is available to the patient divided
by the number of days in the follow-up period
[12]. For this study, the PDC was dichotomized
into C0.80 (adherent) and \0.80 (non-
adherent). The threshold of 0.80 is commonly
used, including by both the PQA and CMS [18,
19]. For completeness, as well as for use in
sensitivity analyses, the Medication Possession
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Ratio (MPR) was also calculated [20] and
dichotomized into adherent (MPR C0.80) and
non-adherent (\0.80) binary measures.
Persistence to liraglutide was defined by the
continuation or discontinuation of the
medication as measured via the days’ supply
reported on pharmacy claims. Discontinuation
was defined as a gap in therapy of at least
90 days and represented non-persistence. The
time to discontinuation was calculated as the
number of days from the index date to the run-
out date of the last fill before the gap in therapy.
Adherence and persistence were defined
separately and represent different aspects of
medication usage; each subject in the study
cohort was defined as either adherent or non-
adherent and also as either persistent or non-
persistent.
Demographic characteristics of subjects
included their age as of the index year, gender,
and geographic region. Also collected were
patient paid amounts for their index
prescription fill and whether or not their
index fill was obtained through a mail order.
Baseline clinical characteristics included A1C at
index, use of antidiabetic medications, and
comorbid conditions. The baseline A1C was
captured from laboratory results on claims
during the 45 days prior to the index date
through 7 days post-index. If multiple values
were present, the A1C result closest to the index
date was used. The dose of the index fill of
liraglutide was obtained, as well as the specialty
of the prescribing physician. Fills for insulin
and OAD medications during the baseline
period were identified and counted at the class
level, and the overall baseline antidiabetic
regimen was categorized into several groups
(no therapy, OAD monotherapy, OAD
combination therapy, insulin monotherapy,
and insulin with OADs). Comorbid conditions
during the baseline period were defined using
the Clinical Classification Software managed by
the Agency of Healthcare Research and Quality
[21], which generates indicator variables for
specific disease conditions based on ICD-9-CM
diagnoses. The comorbidities of dyslipidemia,
hypertension, renal disease, and non-alcohol
fatty liver disease were identified during the
baseline period based on diagnosis, procedure,
and revenue codes appearing on medical
claims. The Diabetes Complications Severity
Index (DCSI) at baseline was created using
ICD-9-CM codes as described in Young et al.
[22] and Chang et al. [23].
During follow-up, several A1C outcomes
were analyzed. The follow-up A1C result
occurring within 90 days of the end of the
1-year follow-up period was captured from
claims. If multiple A1C measures were
available during this period, the one closest to
the end of the 1-year follow-up period was
retained. This A1C result was used to create
indicator variables for A1C \7.0% and B6.5%
achievement at follow-up. Additionally, the
absolute change in A1C from baseline was
calculated, and patients with a reduction of
C1.0% from baseline to follow-up were
identified.
Diabetes-related healthcare resource
utilization during the baseline and follow-up
periods was characterized by binary indicators
and counts of ambulatory visits, emergency
room (ER) visits, and inpatient (IP) stays
related to diabetes. Visits were considered
diabetes-related if they had an ICD-9-CM
diagnosis code of 250.xx in any position.
Consumer Price Index [24] adjusted diabetes-
related healthcare costs were computed as the
combined health plan and patient paid
amounts. Total healthcare costs were
calculated as the sum of medical costs
(categorized into ambulatory visit costs,
emergency services costs, IP costs, and other
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costs) and pharmacy costs. For medical claims,
services were defined as diabetes related if they
had a diagnosis of 250.xx in any position, and
pharmacy costs included oral and injectable
diabetes medications.
Statistical Analysis
All study variables, including baseline and
outcome measures, were analyzed
descriptively. Numbers and percentages were
calculated for dichotomous and polychotomous
variables, while means, medians, and standard
deviations (SD) were calculated for continuous
variables. Results were stratified by the
dichotomous adherence and persistence
measures. Bivariate comparisons were
conducted, and appropriate tests for
significance were performed based on the
distribution of the variable.
Multivariate analysis of the study outcomes
was conducted using appropriate regression
models. Ordinary least squares regression was
used to analyze the absolute reduction in A1C,
while logistic regression was used to analyze
dichotomous A1C outcomes (e.g., A1C goal
attainment). To analyze diabetes-related costs,
generalized linear models with a gamma
distribution and log link were employed,
utilizing Manning and Mullahy’s formulation
[25]. All multivariate analyses were adjusted for
key covariates, including age group, gender,
health plan region, index prescriber specialty,
mail-order status, patient paid amount for
index fill, baseline DCSI, baseline
comorbidities of interest (dyslipidemia,
hypertension, renal disease, non-alcohol fatty
liver disease), baseline count of OAD classes,
baseline insulin use, baseline diabetes-related
utilization, baseline diabetes-related costs (not
included in cost models), and baseline A1C.
Adjusted outcomes and average costs were
predicted and bootstrapped 95% confidence
intervals were estimated. Data extraction and
statistical analysis were performed using SAS
version 9.2 (SAS Institute Inc., Cary, NC).
Statement of Ethics
No identifiable protected health information
was extracted or accessed during the course of
this study; hence, no Institutional Review Board
approval was required.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Sample Selection and Baseline
Characteristics
After applying all inclusion and exclusion
criteria, the final study population included a
total of 1321 liraglutide patients with T2D
(Fig. 1). The mean (SD) age of the sample was
53.0 (9) years, and just over half (51%) were
male (Table 1).
The mean (SD) PDC was 0.59 (0.31); 454
patients (34%) were classified as adherent by
way of a PDC of at least 80%. Sixty percent of
patients were persistent for the entire 365-day
follow-up period, and the mean (SD) length of
persistence was 263 (136) days. Adherent
patients were slightly older and more
frequently male, while the mean DCSI was
similar between adherent and non-adherent
patients (0.57 vs. 0.59, p = 0.783, Table 1), as
was the prevalence of comorbid conditions.
Adherent patients had lower mean baseline A1C
(8.08% vs. 8.29%, p = 0.033). Differences
between persistent and non-persistent patients
mirrored those of the adherent vs. non-
adherent cohorts for several characteristics,
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including age (persistent patients were slightly
older) and mean DCSI (no difference between
persistent and non-persistent patients).
However, there was no significant difference in
gender or baseline mean A1C by persistence
groups, and a higher percentage of persistent
patients had dyslipidemia (84% vs. 78%,
p = 0.007) and non-alcoholic fatty liver disease
(5% vs. 2%, p = 0.012) than did non-persistent
patients (Table 1).
Metformin was the most common
antidiabetic medication used during baseline,
and was significantly more common in
adherent patients (74%) than non-adherent
patients (68%, p = 0.025). Other significant
differences in baseline medication use between
adherent and non-adherent patients included
thiazolidinediones (32% vs. 24%, p = 0.002),
DPP-4 inhibitors (41% vs. 29%, p\0.001), and
meglitinides (5% vs. 1%, p\0.001). There was
no significant difference in the percent of
patients who used sulfonylureas or insulin
between adherence cohorts. The index dose of
liraglutide was fairly evenly split between 1.2
and 1.8 mg, but adherent patients were more
likely to have an index dose of 1.2 mg compared
with non-adherent patients (53% vs. 46%,
p\0.001). Comparisons of baseline
medication use between persistent and non-
persistent patients were similar to those for
adherent and non-adherent patients (Table 1).
A1C Outcomes
Unadjusted A1C outcomes are shown in
Table 2. The reduction in mean A1C from
baseline to follow-up was greater in adherent
patients compared with non-adherent patients
(0.81% vs. 0.42%, p\0.001) and in persistent
patients than in non-persistent patients (0.78%
vs. 0.21%, p\0.001). Additionally, when
compared with the non-adherent cohort,
those in the adherent cohort were more likely
to achieve A1C goals of\7.0% (50% vs. 39%,
p\0.001) and B6.5% (35% vs. 26%, p = 0.001),
and were more likely to have at least a 1.0%
reduction in their A1C (38% vs. 32%,
p = 0.022). Similar results were seen when
persistence cohorts were compared; A1C levels
\7.0% and B6.5%, as well as A1C reductions of
at least 1.0%, were more often attained by
persistent patients than non-persistent patients
(p\0.001 for all three outcomes).
Adjusted, multivariate analysis of the A1C
outcomes confirmed the unadjusted results
(Fig. 2a, b). Specifically, adherent patients had
a significantly larger decrease in A1C and were
more likely to achieve at least a 1.0% reduction
in A1C than their non-adherent counterparts
Fig. 1 Sample selection and attrition. GLP-1 glucagon-
like peptide-1, A1C glycated hemoglobin
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(odds ratio [OR]= 1.86, p\0.001). Additionally,
adherent patients were more likely to achieve an
A1C\7.0% (OR = 1.84, p\0.001) and an A1C
B6.5% (OR = 1.70, p\0.001) than non-
adherent patients. Persistent patients were
more than twice as likely to achieve A1C goal
levels and to experience at least a 1.0% decrease
in their A1C thannon-persistent patients (OR for
A1C\7.0% = 2.37; OR for A1C B6.5% = 2.01;
OR for A1C reduction C1.0% = 2.34; all p values
\0.001). Similar results were produced when
analyses were repeated after stratifying patients




Overall, unadjusted diabetes-related mean (SD)
total healthcare costs per patient were $8186
($12,209) for the final sample. Compared with
non-adherent patients, adherent patients had
lower levels of diabetes-related utilization for ER
(13 vs. 18 visits per 100 patients, p = 0.030) and
IP (6 vs. 9 visits per 100 patients, p = 0.051)
services, resulting in lower unadjusted diabetes-
related medical costs ($2743 vs. $4149,
p = 0.018; Table 3), on average (median
diabetes-related medical costs were similar
between groups). However, adherent patients
had significantly higher mean pharmacy costs
Table 2 Unadjusted glycated hemoglobin (A1C) outcomes by adherence and persistence
Adherence group Persistence group
Adherent Non-adherent p value Persistent Non-persistent p value
Total, N 454 867 795 526
Change in A1C from baseline,
mean (SD)
0.81 (1.54) 0.42 (1.70) \0.001b 0.78 (1.56) 0.21 (1.74) \0.001b
A1C goal attainment (\7.0%) 50 (%) 39 (%) \0.001b 49 (%) 35 (%) \0.001b
A1C goal attainment (B6.5%) 35 (%) 26 (%) 0.001b 33 (%) 24 (%) \0.001b




Fig. 2 Adjusted glycated hemoglobin (A1C) outcomes by
a adherence and b persistence
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than non-adherent patients ($6338 vs. $3568,
p\0.001; Table 3). When medical costs (which
include costs for ambulatory visits, ER services,
IP services, and other services) and pharmacy
costs were summed, the result was a higher total
healthcare cost among adherent patients
($9081 vs. $7717, p = 0.028; Table 3), on
average. After adjustment, total diabetes-
related healthcare costs remained significantly
higher for the adherent group (p = 0.005), with
a predicted (95% confidence interval) cost of
$9419 ($8574–$10,308) versus $7667 ($6903–
$8573) for non-adherent patients (Fig. 3a).
Diabetes-related medical services costs were
lower for persistent patients (adjusted model
p value = 0.017), with a predicted cost
Table 3 Unadjusted diabetes-related health care costs during follow-up by adherence and persistence
Adherence group Persistence group
Adherent Non-adherent p value Persistent Non-persistent p value
Total, N 454 867 795 526
Medical costs
Mean (SD) $2743 ($8065) $4149 ($13,383) 0.018a $3103 ($10,124) $4516 ($14,017) 0.047a
Median $683 $687 $682 $699
Inpatient costs
Mean (SD) $1134 ($7157) $1805 ($9410) 0.148 $1402 ($9198) $1835 ($7903) 0.363
Median $0 $0 $0 $0
Ambulatory costs
Mean (SD) $1377 ($3140) $1917 ($5164) 0.019a $1470 ($3643) $2127 ($5685) 0.019a
Median $535 $539 $526 $550
Emergency room costs
Mean (SD) $50 ($238) $106 ($367) \0.001b $59 ($268) $129 ($401) \0.001b
Median $0 $0 $0 $0
Other medical costs
Mean (SD) $182 ($487) $320 ($4118) 0.330 $172 ($457) $426 ($5276) 0.272
Median $89 $81 $86 $80
Pharmacy costs
Mean (SD) $6338 ($2639) $3568 ($2439) \0.001b $5571 ($2658) $2931 ($2298) \0.001b
Median $5606 $3074 $5039 $2341
Total costs
Mean (SD) $9081 ($8685) $7717 ($13,679) 0.028a $8675 ($10,611) $7447 ($14,270) 0.092




350 Adv Ther (2015) 32:341–355
difference of about $1500 ($3298 vs. $4805;
Fig. 3b) compared to patients who discontinued
liraglutide. Total diabetes-related healthcare
costs, however, were higher for persistent
patients than for non-persistent patients
driven by higher pharmacy costs (Table 3;
Fig. 3b; adjusted model p value = 0.010).
DISCUSSION
Liraglutide patients who were adherent had
better A1C outcomes and higher total
diabetes-related healthcare costs than their
non-adherent counterparts—driven by higher
pharmacy costs. Similar results were observed
when comparing patients split into either
persistent or non-persistent groups. The fact
that those classified as adherent and/or
persistent had higher pharmacy costs is not
unexpected, given that these cohorts include
patients who consistently adhered to their
medication and continued to fill their
prescriptions as directed, while those in the
non-adherent and non-persistent cohorts did
not. It is likely that adherent and persistent
patients experienced better A1C outcomes as a
direct result of their consistent medication use,
demonstrating that the additional cost comes
with improved clinical outcomes. However,
adherence to other medications was not
directly assessed. Those in the adherent and
persistent groups had a significantly higher
number of baseline OAD medications on
average, which could indicate a higher degree
of familiarity with medications in general or
with adhering to prescribed medications.
Additionally, while non-adherent and non-
persistent patients had lower pharmacy costs,
mean diabetes-related medical costs were
significantly higher in non-persistent patients
and trended towards being significantly higher
(p = 0.082) in non-adherent patients. It is
possible that the additional medical costs
among these patients may have been due, at
least in part, to how well their diabetes was
managed (as evidenced by worse A1C
outcomes), and may have been lower had they
been more adherent or persistent to their
medication. Further, since the median
diabetes-related medical costs were similar
between adherent and non-adherent patients
(and between persistent and non-persistent
patients), there is likely a subset of non-
adherent (and non-persistent) patients who
contributed very large diabetes-related medical
costs, perhaps as a result of their non-adherence
and/or non-persistence.
Direct comparisons of our results to
previous studies require careful consideration,
Fig. 3 Adjusted follow-up diabetes-related cost by
a adherence and b persistence
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since most of the current literature on diabetic
medication adherence involves OADs or
insulin. However, our mean adherence rate of
59% is within the range of 36–87% reported by
Lee et al. [10], although the authors measured
adherence by MPR and included OADs and
insulin. In a 2006 article, Ho et al. [12] reported
that 79% of patients had PDC of at least 80%,
which is noticeably higher than in our study,
where only 34% had a PDC C80%. However,
the PDC in the article by Ho et al. was a
summary measure potentially of multiple
medications, and referred to oral
hypoglycemic agents. A study by Rhee et al.
[14] reported an adherence of[75% in only 8%
of patients, but the study years were 1991
through 2001 and adherence was measured as
the percentage of visits in which self-reported
diabetic medication use was as recommended
at the preceding visit. In other studies offering
a direct comparison of our findings of
adherence to liraglutide, patients using
liraglutide between 2010 and 2011 had a
mean MPR of 70%, with 46% of patients
being at least 80% adherent [26]. In another,
more recent study involving GLP-1 receptor
agonist use, 14,211 liraglutide patients had a
median unadjusted PDC of 0.72 [27]. In our
study, the average adherence rate was 0.65
using PDC and 72% using MPR with 45% of
patients having an MPR of at least 80%,
indicating a very similar level of adherence to
these studies.
Although our study suggests that better
adherence and persistence are associated with
better A1C outcomes, there are potential
barriers to adherence that need to be
addressed. Patient attitudes, beliefs, and
knowledge about diabetes, as well as culture,
language capabilities, financial resources,
comorbidities, and social support, have all
been cited as potential barriers [28]. Other
challenges for patients may include paying for
medications, remembering doses, reading
prescription labels, and obtaining refills [29].
More frequent administrations may also be
linked to adherence, as taking more than two
doses of diabetes medication daily has been
associated with higher A1C levels [29], and in a
comparison of injectable GLP-1 receptor
agonists, patients using once-daily liraglutide
were more adherent than those using twice-
daily exenatide [26].
Claims database analysis allows for
estimation of real-world treatment patterns,
and the strength of our analysis derives from
the large, geographically diverse population
studied. The plans used for analysis include a
wide geographic distribution across the US, and
therefore provide the capability for
generalization to managed care populations on
a national level, although such generalizations
should be made with caution since those
selected for this analysis may represent a select
patient population. All retrospective database
analyses are subject to certain limitations,
however, and the results of this study must be
interpreted with appropriate consideration of
these limitations. Claims data are collected
primarily for payment purposes, not research,
and are subject to coding errors. The presence of
a claim for a filled prescription does not
necessarily indicate that the medication was
consumed or that it was taken as prescribed.
Additionally, the data have no information on
patient weight, body mass index, or blood
pressure. Lab results were only available for a
subset of patients (those without lab data were
excluded), and only include those performed by
a lab during a patient visit; therefore, they may
not completely represent A1C outcomes in T2D
patients treated with liraglutide. Data used for
this study came from a commercial managed
care population with 18 months of continuous
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health plan enrollment who also had multiple
A1C results during a specific time frame around
GLP-1 therapy initiation. Therefore, results of
this analysis are primarily applicable to T2D
patients on similar therapies in stable managed
care settings receiving frequent care from their
providers. Adherence to medications other than
liraglutide was not assessed or controlled for,
and if differences in adherence to other
medications existed, this could potentially
have impacted the results. Finally, it is
possible that positive feedback improves
adherence; therefore, observable
improvements in A1C could have induced
patients to be more adherent.
CONCLUSION
In this study, we sought to examine how
adherence and persistence to once-daily
liraglutide impact glycemic control and
healthcare costs in a real-world T2D
population. Patients included in this study
who were adherent or persistent to liraglutide
had better adjusted A1C outcomes than those
who were not. Persistent patients had
significantly lower diabetes-related medical
costs compared to patients discontinuing
liraglutide. However, total diabetes-related
costs were higher in adherent and persistent
patients than in their non-adherent and non-
persistent counterparts, which were largely
driven by their higher pharmacy costs. This
study highlights the importance of adherence
and persistence on diabetes control and
associated healthcare costs. These results will
assist payers and policy makers in making
informed decisions by highlighting the impact
and importance of medication adherence to
liraglutide on clinical and economic outcomes.
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Medical claim for T2D (ICD-9-CM diagnosis
code of 250.x0 or 250.x2) and no claims for type
1 diabetes mellitus (T1DM), identified with
ICD-9-CM diagnosis codes 250.x1 or 250.x3.
Diagnosis codes in any position were used;
OR C1 claim for an OAD including
sulfonylureas, metformin, thiazolidinediones,
a-glucosidase inhibitors, meglitinide
derivatives, DPP-4 inhibitors, SGLT2 inhibitors,
bromocriptine 0.8 mg, or combination
medications and no claims for T1D.
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